The Discounted Cash Flow (DCF) valuation of Xeris Pharmaceuticals Inc (XERS) is (42.17) USD. With the latest stock price at 4.75 USD, the upside of Xeris Pharmaceuticals Inc based on DCF is -987.7%.
Based on the latest price of 4.75 USD and our DCF valuation, Xeris Pharmaceuticals Inc (XERS) is a sell. selling XERS stocks now will result in a potential gain of 987.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.0% - 10.3% | 8.2% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (167.78) - (24.72) | (42.17) |
| Upside | -3632.3% - -620.5% | -987.7% |